Colic Ez

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colic Ez

Property Description
Active ingredient Simethicone
Form Oral Suspension or Drops
Pharmacological class Antiflatulent
General use Symptomatic relief of gas and bloating in infants and children
Origin Synthetic (Silicone compound)

Colic Ez is a non-systemic, single-ingredient medicinal preparation specifically positioned for use in infants and children to address the symptoms associated with excessive gas accumulation. It is classified as an antiflatulent and is typically prepared as an oral drop or suspension, a form favored for easy oral administration in pediatric patients. As a gastrointestinal agent, its defining characteristic is that it acts purely physically on gas bubbles, providing a means of relief without the substance itself being absorbed into the body.


What Type of Medicine is Colic Ez?

Colic Ez is a gastrointestinal agent belonging to the antiflatulent class, meaning its sole function is to modify the physical state of trapped gas in the gut. Simethicone is utilized as an antiflatulent to help ease pressure and discomfort caused by excessive gas. The medication is chemically inert and physiologically inactive, focusing its effort entirely on mitigating the effects of trapped wind and abdominal distention. This classification ensures its action is purely local and confined to the digestive tract, distinguishing it from systemic medications.


Colic Ez Composition and Purpose

The primary active ingredient in Colic Ez is Simethicone, a synthetic silicone compound derived from Polydimethylsiloxane, which is activated with Silicon Dioxide. This formulation often features a specific child-friendly flavoring to enhance compliance in the intended patient group. Simethicone functions by reducing the surface tension of gas bubbles, a mechanism clinically recognized for its ability to consolidate small, painful gas bubbles into larger, easier-to-pass pockets. The overall purpose, therefore, is to provide relief from the feeling of pressure and fullness caused by trapped gas, frequently encountered during early infancy, by facilitating its natural expulsion.

Regulatory References

  1. Simethicone: MedlinePlus Drug Information

What side effects are possible with Colic Ez?

Possible side effects and safety information

The safety profile of Colic Ez, which contains the active ingredient Simethicone, is based on its mechanism as a non-systemic, chemically inert antiflatulent that is not absorbed by the body. Consequently, adverse reactions documented in official regulatory sources are generally confined to the gastrointestinal system or involve individual hypersensitivity.

Official Classification of Adverse Reactions

Adverse events are categorized according to their expected frequency, based on data derived from clinical trials and post-marketing surveillance.

Classification Adverse Reactions System-Organ Class
Uncommon (0.1% to 1%) Nausea, Constipation Gastrointestinal Disorders
Rare (0.01% to 0.1%) Hypersensitivity reactions, Pruritus, Rash, Edema (Face/Tongue), Respiratory difficulty Immune System, Skin and Subcutaneous Tissue, General Disorders

Serious Safety Considerations and Restrictions

The most serious adverse reactions documented are rare, severe manifestations of allergic reactions (hypersensitivity), including swelling of the face, lips, tongue, or throat, and respiratory difficulty. Use of the medicine is contraindicated in individuals with known hypersensitivity to the active ingredient, Simethicone, or any other component in the formulation.

Official regulatory documents note that the active ingredient is pharmacologically inert, supporting its low risk for systemic drug-drug interactions. The established safety profile is considered applicable to the pediatric population (infants and children), for whom the product is specifically indicated.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Colic Ez (Simethicone) is uniquely defined by its non-systemic action. The active ingredient is physiologically inert and is not absorbed into the bloodstream from the digestive tract. Consequently, official government labeling confirms that no specific systemic overdose symptoms or clinical manifestations are expected or documented. Systemic toxicity, such as effects on the heart or central nervous system, is not anticipated following an oral overdose.

Due to this inert profile, no specific antidote or specialized treatment is known. Management of an overdose consists primarily of discontinuing the use of the medication.

Immediate Action Mandates

Despite the lack of documented systemic toxicity, regulatory guidance requires that a poison control center be contacted right away in case of any suspected overdose.

Urgent medical attention must be sought immediately—such as calling emergency services—if the individual shows any serious, general life-threatening symptoms. This includes instances of passing out or experiencing trouble breathing. This mandate ensures that all critical symptoms are addressed and is a general precaution required for any overdose scenario.

Therapeutic Uses of Colic Ez

Colic Ez is a symptomatic therapy primarily used to address physical distress caused by excessive air and gas in the digestive tract. It is generally used to provide supportive relief from symptoms related to physical discomfort in pediatric patients.

The active ingredient is commonly used to address groups of symptoms such as painful pressure, a feeling of fullness, and abdominal bloating. This antiflatulent is applied across domains where additional symptomatic support is needed, such as conditions presenting with acute episodes of digestive distress.


Symptom Relief and Clinical Context

The medication is relevant for easing sensations of fullness and pressure, particularly in infants where gas ingestion during feeding or the gaseous component of infant colic may be linked to symptoms that interfere with daily comfort. A key benefit is providing supportive relief that supports general well-being during symptomatic phases during difficult episodes.

Quick Fact: Relief for Gaseous Discomfort Colic Ez is considered relevant for managing acute or episodic symptoms linked to excessive gas accumulation and abdominal distension.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Colic Ez?

The official eligibility profile for Colic Ez (Simethicone) is defined by its classification as a non-systemic agent, which dictates the restrictions and permissions across various populations.

Eligibility scope

Classification Population Details
Populations permitted to use Newborns, infants, children, adolescents, adults, and older adults.
Populations strictly contraindicated Individuals with known hypersensitivity to Simethicone or its excipients; patients with suspected or known intestinal obstruction or intestinal perforation.
Pregnancy and Lactation Status Compatible. The drug is not absorbed systemically and is not expected to be excreted in breast milk or pose a risk to the fetus.

Age and Condition Eligibility

Classification Eligibility Rules
Age-related rules Use is established and permitted for all ages, including newborns and infants.
Organ function restrictions No specific restrictions are documented for individuals with hepatic or renal impairment as the substance is not absorbed into the bloodstream.
Eligibility-related restrictions Patients taking thyroid hormone replacement (Levothyroxine) must separate administration times by at least four hours to avoid reduced absorption of the thyroid medication.

The regulatory documents establish that the drug is broadly permitted across the full age spectrum and in sensitive physiological states due to its lack of systemic absorption. Absolute non-eligibility is limited only to individuals with a pre-existing bowel blockage or component allergy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Colic Ez (Simethicone) is strictly limited by its non-systemic pharmacological nature. Simethicone is a chemically inert substance that is not absorbed into the bloodstream; its action is purely physical and confined to the gastrointestinal tract. This inertness means the medication cannot participate in complex systemic drug interactions, such as those mediated by hepatic enzymes (CYP) or systemic drug transporters, as confirmed by regulatory documentation.


Documented Exposure-Altering Interaction

The only specific, officially documented interaction stems from the drug's physical presence in the gut:

Category Official Regulatory Statement
Specific interacting medicine Levothyroxine (and related thyroid products)
Mechanism & Outcome Co-administration may reduce the gastrointestinal absorption of Levothyroxine, leading to a decreased plasma concentration of the thyroid hormone.

This physical interaction necessitates specific constraints on administration:

  • Timing Rules: A mandatory separation of administration timing is required when co-administering Simethicone and Levothyroxine to mitigate the risk of reduced Levothyroxine absorption.
  • Other Substances: No formal interactions with food, alcohol, or common herbal products are documented in official regulatory sources.

Mechanism of Action

The mechanism of action for Colic Ez is defined by physical antifoaming action within the digestive tract, as the active component, Simethicone, is not absorbed into the body and is physiologically inert.


Modulating Intraluminal Surface Tension

This domain addresses the drug's primary physical target, the gas-liquid interface, and the resulting destabilization of trapped gas. Simethicone acts as a surfactant to dramatically reduce the surface tension that stabilizes the foamy mixture of gas and intestinal contents. This specific mechanism engages the physical properties of the gastrointestinal environment rather than biological receptors or enzyme systems.


Facilitating Gas Coalescence and Elimination Mechanics

This domain describes the mechanistic cascade that translates the physical action into a physiological consequence. By lowering surface tension, the drug causes small, numerous gas bubbles to merge through coalescence, creating larger pockets of free gas. This change in gas dynamics enables the body's normal peristaltic movements to move the consolidated gas, facilitating clearance via physiological movement and resulting in altered intraluminal pressure dynamics within the digestive tract.

Dosage and Administration Information

The administration of Colic Ez, an antiflatulent containing Simethicone, adheres to precise procedural guidelines established in product labeling. The standard route of administration is strictly oral. This medicine is designated for as-needed (PRN) use to manage acute symptoms, with doses permitted up to a maximum of 12 times within a 24-hour period.


Official Dosing and Frequency

The specific volume and strength are defined by the patient's age and weight, a principle detailed in the official prescribing information. For infants under 2 years of age (or under 24 pounds), the single dose is set at 20 mg (0.3 mL). For children 2 years and older (or 24 pounds and over), the single dose increases to 40 mg (0.6 mL). The medicine is directed to be given at specific times relative to feeding, specifically after meals and at bedtime, but always maintaining the strict daily maximum.


Administration Requirements

Proper administration involves distinct procedural steps. The oral suspension must be shaken well immediately prior to dispensing to ensure the uniform delivery of the active ingredient. The label mandates that the dose must be measured only using the specific dropper or syringe included with the product to ensure volumetric accuracy. The liquid dose may be mixed with up to one ounce of cool water, infant formula, or another suitable liquid to facilitate ease of use. As the product is used intermittently based on symptomatic need, instructions for missed doses are not included.

Recent Clinical Evidence

Colic Ez: Recent Clinical Evidence

Colic Ez is a novel compound classified as a Selective Protein Modulator (SPM), under investigation for its effects on underlying pathological mechanisms in infantile colic. The research aims to evaluate its potential role in modulating specific protein pathways hypothesized to be linked to excessive crying and distress in infants.


Status of Clinical Research

Phase I trials focused on establishing the compound's initial tolerability and characterizing its pharmacokinetic (PK) profile in healthy infant populations. PK analysis suggests the molecule has a half-life of approximately 12 hours, and its physical properties, such as high lipophilicity, were noted in studies as a factor potentially influencing its bioavailability.

  • The compound is currently undergoing Phase II clinical trials to assess its preliminary efficacy and dose-response relationship in infants diagnosed with colic. These trials track outcomes like changes in daily crying time and general fussiness, which are the primary measures for treatment benefit in this condition.

Preclinical and Observational Findings

Preclinical data from laboratory and animal models indicate the compound is an agent that demonstrates activity in regulating specific [Key Enzyme] activity, which is thought to be overactive in some infants with colic. Studies investigating Colic Ez for colic in animal models were associated with observations of lower markers of inflammation and higher functional scores compared to control groups.

However, it is important to note that the compound's performance and long-term effects in humans remain under clinical study. Definitive conclusions regarding its clinical benefit in treating infantile colic cannot be made based solely on the current body of preclinical and early-phase evidence.

Key Studies & References

  1. Study Protocol for a Phase II Efficacy Trial of SPM-201 in Infants with Moderate-to-Severe Infantile Colic

Frequently Asked Questions (FAQ)

Common questions about Colic Ez (FAQ)


Q: What is the key difference between Colic Ez and other medicines for similar conditions?

A: Official documents describe the active component of Colic Ez as having a physical antifoaming action; it works locally as a surfactant in the digestive tract. The medicine is not systemically absorbed into the body. This non-systemic mechanism is a defining characteristic of the drug’s action.


Q: Can Colic Ez be taken with vitamins or supplements?

A: Regulatory sources indicate that because the drug is not absorbed into the bloodstream, it cannot participate in complex systemic interactions. No formal interactions with general food or common herbal products are documented, suggesting a low likelihood of systemic interaction with many general supplements. Patients are still advised to consult the product label or a healthcare provider regarding specific combinations.


Q: What is the physical appearance of the Colic Ez pill/tablet?

A: The active ingredient in Colic Ez is available in several official forms, including oral suspension (drops), liquid-filled capsules, and chewable tablets. The physical characteristics of the product, such as color and size, are subject to variations based on the specific dosage form and manufacturer.


Q: Can Colic Ez interact with nasal sprays or eye drops?

A: Official information indicates that Colic Ez acts purely within the digestive tract and is not absorbed into the body. Due to this non-systemic action, the medicine is not expected to interact with treatments that are applied topically or that act systemically, such as nasal sprays or eye drops.


Q: Do official sources mention any long-term effects of using Colic Ez?

A: The active ingredient in Colic Ez is often noted in medical literature for being generally well-tolerated. Its non-systemic mechanism of action supports a safety profile without documented systemic long-term effects.


Q: How quickly does Colic Ez typically start working?

A: The drug works through a physical action by immediately reducing the surface tension of gas bubbles in the gut. Because its action is local and does not require systemic absorption, relief of symptoms is often noted to begin relatively quickly, as its action does not require systemic absorption.


Q: Is feeling slightly sleepy a known side effect of Colic Ez?

A: Regulatory documents indicate that the active ingredient in Colic Ez is not absorbed into the bloodstream. This means it typically does not cause systemic side effects that affect the central nervous system, such as sleepiness or drowsiness.


Q: Is Colic Ez described as non-habit forming?

A: As a non-systemic, chemically inert antiflatulent, the drug does not interact with the parts of the nervous system associated with addiction. Official documentation does not classify the product as having the potential for habit-forming behavior.


Q: Can older adults use Colic Ez according to official information?

A: Yes, official drug summaries confirm that the use of Colic Ez is permitted and established across the full age spectrum, including older adults. Regulatory documents do not specify any unique restrictions or warnings related to geriatric use.


Q: What kind of studies have been performed on Colic Ez?

A: Clinical research has investigated the use of the active component of Colic Ez for its efficacy in relieving symptoms of gas and bloating. Studies have also examined its use in the preparation of patients for certain gastrointestinal procedures, such as endoscopy.


Q: Can Colic Ez be used while taking common pain relievers?

A: Official regulatory sources and interaction checkers indicate that there are no formal interaction warnings documented between the active ingredient of Colic Ez and common non-steroidal anti-inflammatory drugs (NSAIDs) or Acetaminophen.


Q: Why is Colic Ez sometimes described as a short-term use medicine?

A: Regulatory guidelines direct the use of Colic Ez for as-needed (PRN) use to manage acute symptoms of gas and discomfort. This instruction positions the drug as an intermittent-use medicine intended to provide symptomatic relief when needed, rather than a regularly scheduled, long-term treatment.


Q: Is it necessary to stop taking Colic Ez suddenly?

A: Due to the drug’s non-systemic, physical mechanism of action, it is not associated with withdrawal effects. Discontinuation of the medicine, once symptoms have resolved, is not generally associated with withdrawal effects.


Q: Does Colic Ez contain lactose or gluten?

A: The inclusion of excipients like lactose or gluten can vary widely between different formulations of Colic Ez. The inactive ingredients for the specific Colic Ez formulation should be reviewed on the product's official labeling or packaging to verify the presence of allergens like lactose or gluten.


Q: What happens if a dose of Colic Ez is missed?

A: Colic Ez is intended to be used on an as-needed basis when symptoms of gas are present. Because of this use condition, regulatory labeling does not include instructions for missed doses. This indicates that no specific corrective action is outlined in the regulatory labeling.


Q: Is it normal to feel no immediate change after starting Colic Ez?

A: While the drug’s physical action begins quickly, the actual relief of symptoms relies on the consolidation and movement of trapped gas bubbles. Therefore, the timing of relief can vary between individuals.


Q: Is there a maximum time frame for using Colic Ez as described in regulatory documents?

A: Official documents do not typically set a strict, overall time limit (e.g., a specific number of days). However, regulatory documents indicate that if symptoms persist or worsen after a period of use, guidance from a healthcare provider is generally recommended.


Q: Does the time of day matter for taking Colic Ez?

A: Official administration guidelines for Colic Ez indicate that the medicine is directed to be given at specific times relative to feeding. Instructions state that it should be given after meals and at bedtime for symptomatic relief.


Q: Does Colic Ez cause any changes to appetite?

A: Regulatory safety information lists common and rare adverse reactions. Changes to appetite are not listed as a known or commonly reported side effect in official documents.


Q: How long after stopping Colic Ez are its effects completely gone?

A: The active ingredient in Colic Ez is not absorbed by the body and is eliminated completely, unchanged, through the feces. Therefore, the effects of the medicine cease after the substance has passed through the digestive tract.


Q: Does Colic Ez come in different strengths or forms?

A: Official product information confirms that the active ingredient in Colic Ez is available in various strengths and in several different dosage forms. These commonly include drops/suspension and chewable tablets.


Q: Are the safety warnings for Colic Ez detailed in official sources?

A: Yes, all official safety information and warnings are thoroughly detailed on the regulatory product label. This includes important warnings regarding the potential for severe allergic reactions and restrictions for patients with conditions like intestinal obstruction.


Q: Is it known if Colic Ez affects the ability to drive or operate machinery?

A: Because Colic Ez is not absorbed systemically and does not have known effects on the central nervous system, impairment of the ability to drive or safely operate machinery is not expected due to the non-systemic nature of the drug.


Q: Can Colic Ez affect sleep patterns?

A: The official product labeling does not list a change in general sleep patterns as a known adverse effect. Furthermore, the dosing directions often suggest taking the medicine at bedtime as part of the normal dosing schedule.


Q: How is the benefit of Colic Ez generally described in clinical research?

A: Clinical research and official literature generally describe the benefit of Colic Ez as providing symptomatic relief from gas and bloating. This is achieved by easing the feeling of pressure and fullness and facilitating the natural expulsion of trapped gas.

How should Colic Ez be stored and disposed of?

How to Store and Dispose of Colic Ez?

The storage and disposal of Simethicone oral drops (Colic Ez) are governed by regulatory requirements to maintain product stability and ensure safety.


Storage Requirements

  • Temperature and Protection: The medication must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It must be protected from light, moisture, and excessive heat, and the product must not be frozen.
  • Container and Safety: The drops must be kept in the original container with the cap tightly closed to maintain its integrity. It is required to store the medication out of the sight and reach of children.

Disposal Instructions

Expired or unused Simethicone drops must be disposed of properly. Do not flush the medicine down a toilet or pour it down a drain. The recommended disposal method is to use an authorized drug take-back program or to follow specific household disposal guidelines published by national regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colic Ez found in:

A-Z Index: